Haleon plc (LON:HLN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Haleon plc (LON:HLN) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is GBX 407.

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group reissued a “buy” rating and issued a GBX 450 price target on shares of Haleon in a research note on Wednesday, January 21st. Deutsche Bank Aktiengesellschaft cut their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Berenberg Bank upped their target price on Haleon from GBX 510 to GBX 512 and gave the company a “buy” rating in a report on Thursday. Finally, JPMorgan Chase & Co. increased their target price on shares of Haleon from GBX 315 to GBX 335 and gave the company an “underweight” rating in a research report on Wednesday, November 26th.

Haleon Stock Performance

Shares of Haleon stock opened at GBX 380.30 on Friday. The stock has a market cap of £33.87 billion, a price-to-earnings ratio of 20.56, a P/E/G ratio of 1.49 and a beta of 0.25. Haleon has a twelve month low of GBX 325.10 and a twelve month high of GBX 419.50. The company’s fifty day moving average is GBX 385.67 and its 200 day moving average is GBX 367.32. The company has a quick ratio of 0.93, a current ratio of 0.87 and a debt-to-equity ratio of 53.60.

Haleon (LON:HLN) last announced its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.40% and a net margin of 13.81%. Sell-side analysts forecast that Haleon will post 19.5033282 EPS for the current year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.